Hospital Acquired Disease Testing Market to Benefit from Increasing Infection-related Hospitalization, to Expand at 19.3% CAGR by 2019

The market study offers an extensive analysis of the global hospital acquired disease testing market, which includes a comparative analysis of the past and present behavior of this market. The report also examines the growth prospects of this market in the coming years.The report states that the increasing prevalence of healthcare associated infections (HAIs) and resistance to drugs of an increasing number of pathogens are the primary factors driving the hospital acquired disease testing market. 

In addition, the implementation of prevention codes by several governments around the world to keep a check on HAIs is furthering the growth of this market. Stringent regulations in place combined with expiration of PCR (pre-hospital care report) patents will aid growth of the hospital acquired disease testing market.However, the report states that in developing economies, inadequate funds, lack of skilled labor, and insufficient quality control mandates slow down the growth of this market.

The global market for hospital acquired disease testing is divided on the basis of infection types and geography. By infection type, the market is segmented into urinary tract infection (UTI) testing, pneumonia testing, methicillin-resistant staphylococcus aureus (MRSA) testing, surgical site infection (SSI) testing, blood stream infection (BSI) testing, and others (GI, respiratory, bone, cardiovascular, etc.).By geography, the global hospital acquired disease testing market is spread across North America, Asia Pacific, Europe, and Rest of the World.By infection type, currently, the urinary tract infection testing segment leads the market and is expected to rise at an 18.1% CAGR for the forecast period. As such, the UTI segment will be valued at US$2.1 bn by 2019.

However, the SSI testing and pneumonia testing segments will also exhibit high demand from developing countries in Asia Pacific in the next few years. In this region, the growth of the hospital acquired disease testing market has been beneficial for progressive clinical research into the behavior of various pathogens. The increasing demand for reduced healthcare costs from both healthcare institutions and patients has been aiding growth of the hospital acquired disease testing market and its allied markets as well. 

Microbiology Culture Market to exceed US$7.59 bn by 2023, Bacterial Culture Media to Lead Growth

The microbiology culture market has grown significantly in the last few decades in terms of demand in various end-user industries. Academia, clinical research organizations, and commercial end-user industries such as pharmaceutical, cosmetics, and food and beverage are providing impetus to the global microbiology culture market. The increasing potential of bioprocessing and biopharmaceutical applications has driven demand for microbiology culture media products.

The microbiology culture media market is witnessing strong growth due to factors such as increasing food concerns worldwide, rising number of food product recalls, and growing impact of press coverage on food processing industries. The bacterial culture media segment accounted for the larger share of the global microbiology culture market in 2014. Moreover, the segment is likely to continue its dominance during the forecast period from 2015 to 2023 due to expected rise in application in food microbiology, pharmaceutical microbiology, and disease research. In terms of culture media, the complex media segment held the largest share of the global microbiology culture market in 2014, followed by other market segments such as synthetic media, special media and simple media. Demand for complex media is likely to witness continuous growth during the forecast period as it provides full range of growth factors required to cultivate unknown bacteria or bacteria with complex nutritional requirements. Additionally, demand for ready-to-use, off the shelf products in dehydrated and prepared culture media has increased significantly. This is expected to propel the segment in the near future.

Microbiology culture is the process of culturing microbiological organisms, wherein microorganisms are allowed to reproduce and multiply (grow in number) in a predetermined culture media and controlled laboratory conditions. Various culture methods with a vast range of culture media have been developed for the identification and characterization of microorganisms and are increasingly being used across the world. Presently, these microbiology cultures are used by microbiologists on a large scale in food, beverages, pharmaceuticals, research, cosmetics, and several other industries.

Key factors driving the global microbiology culture market are high demand for improved antibiotics, increasing food microbiology, rising life science research funding, and high prevalence of foodborne and other infectious diseases. 

Request a Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3232

Moreover, the microbiology culture market is witnessing strong growth due to rising food safety concerns, increasing number of food recalls, evolving pathogens, growing press coverage and public awareness, and increasing demand in other industries. Additionally, the industry is expected to expand at a rapid rate due to increased food sourcing due to rise in global food demand and supply. This, in turn, would require advanced culture methods and media for fast and accurate microbial analysis. Microbiology culture methods are the principal diagnostic methods used to determine the cause of infectious diseases by culturing the pathogen in a preset medium.

Read more: http://www.transparencymarketresearch.com/microbiology-culture-market.html

Population Health Management Solutions - How it works?

The terminology population health is defined as the outcome of health analyzed in a group of individuals. These groups are often geographic population such as communities or nations, but they also refer to groups such as disabled persons, ethnic groups, employer groups, prisoners and any other groups. This approach aims at improving the health of entire human population as health outcome of such groups is of relevance to policy makers in both public and private sectors. The landscape of healthcare industry is rapidly changing and patients clinical needs and delivery models have become complex. Thus, for providing better clinical care doctors, nurses, physicians, government bodies, employers and others are increasing adopting patient health management solutions across the globe. The introduction of patient health management solutions enable improved healthcare quality with reduced cost.

Aging population, technological advancements and improved demand for quality life and health are
the key factors that are anticipated to increase the market size of population health management solutions. Rising number of chronically ill patients and increasing focus on reduction of healthcare expenditure across the globe would also stimulate the demand for population health management solutions. However, lack of skilled labor especially in developing countries, huge investments and security of patient’s data are the key reasons that might impede the growth of this market.


Request a Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4174

The population health management solutions market is highly fragmented hence intense competitive rivalry is witnessed among the players. Major players operating in this market are focusing on growth strategies such as mergers and acquisitions, agreements, collaborations, partnerships, innovations, marketing campaign and other promotional activities as to increase their market share. The prominent players operating in population health management solutions market includes. Cerner Corporation, Allscripts Healthcare Solutions, Inc., Explorys, Inc., Conifer Health Solutions, LLC, Healthagen, LLC. (A Subsidiary of Aetna, Inc.), Health Catalyst, LLC, Phytel, Inc., I2i Systems, Inc., Mckesson Corporation, Verisk Health, Inc., Wellcentive, Inc. and other major players. These players dominate the market due to innovative and highly effective products.

Rapidly Growing Geriatric Population to Boost Bone Morphogenetic Proteins Market Valuation to US$587.069 mn by 2022

Bone morphogenetic proteins (BMP) are naturally occurring proteins found in the human body. Identified in 1965 by Marshall Urist, bone morphogenetic proteins are among the most potent growth factors that induce mesenchymal stem cells to differentiate into osteoblast cells. Twenty different types of BMPs have been discovered to date; only BMP 2, 7 and 9 have osteoinductive property and have been proven to play a significant role in bone formation. However, of these, only BMP-2 and BMP-7 are commercially available. These proteins trigger intracellular signal pathways by binding to the receptor of the mesenchymal stem cells resulting in transformation of stem cells into tissue specific progenitor cells. These cells are involved in the synthesis of musculoskeletal tissue formation, extracellular growth and matrix.

The bone morphogenetic proteins market report studies the current scenario as well as future market potential for bone morphogenetic proteins globally. The market overview section of the report comprises qualitative analysis of the overall bone morphogenetic proteins market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s Five Forces analysis and market attractiveness analysis. In addition, various analyses such as event regulatory scenario and value chain analysis have also been provided. Value chain analysis includes the study of major steps involved in the recombinant bone morphogenetic proteins preparation and distribution. Regulatory scenario includes the study of different regulatory norms and procedures that regulate the approval and commercialization of recombinant bone morphogenetic proteins products.

Request a Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2308

Bone morphogenetic proteins (BMPs) that are classified under transforming growth factor beta superfamily are multifactorial growth factors. These are naturally occurring proteins found in the human body, involved in numerous cellular responses. BMPs were first isolated in 1965 by scientist Marshall Urist for the ability to induce the formation of bone and cartilage. To date over 15 BMPs have been isolated and cloned. However, only BMP-2 and BMP-7 are considered to show the greatest amount of osteoinductive potential. Both the types of BMPs share similar kind of cell receptors (Type 1 and Type 2 BMP receptor) that help in regulating bone growth. Thus, for clinical use, BMPs are produced through recombinant DNA technology namely rhBMP-2 and rhBMP-7. These BMPs have been approved by the FDA for use in orthopedic applications such as spinal fusions, oral surgery, and tibia non-unions. These proteins posses the ability to induce patients own cells for bone formation.

In addition, BMPs have proved to be beneficial for patients undergoing spinal fusion surgery by eliminating the need for bone harvesting from the pelvis region. This innovative research approach also reduces the amount of pain, dependence on spinal rods or screws, and augments the rate of spinal fusion. Although, BMPs have proved to be a noteworthy bone graft substitute in spinal fusion, a variety of complications are associated with its off-label usage. Uncontrolled bone formation, bone overgrowth, male sterility, leg pain, back pain, respiratory complication, and inflammation are some of the side effects associated with the implant of BMPs. Thus, the market for BMPs has been restricted by biocompatibility issues, high cost, strict regulations, and presence of numerous bone graft substitutes.

In terms of regional distribution, North America currently accounts for the largest share of the bone morphogenetic proteins market, followed by Europe. Furthermore, North America, with a market share of over 70%, is expected to dominate the industry during the forecast period. This leadership would be witnessed due to high awareness about BMP products, availability of premium priced recombinant BMP products, and soaring number of spinal fusion procedures. Furthermore, highest growth of this industry is expected to emerge in Asia Pacific during the forecast period. The global bone morphogenetic proteins market is characterized by three players namely Medtronic plc, Olympus Biotech, and Cellumed.

Know more: http://www.transparencymarketresearch.com/bone-morphogenetic-protein-market.html

Food Giant Nestlé Ventures Forth into Diagnostic Devices Industry with Alzheimer’s Detection Test

The medical devices industry is brimming with opportunities, enticing behemoths from the technology domain, such as Apple and Google, to venture into this territory. And now, an unlikely contender hopes to cash in on the lucrative opportunities that exist in the med devices industry. Food giant Nestlé is venturing forth with a diagnostic device that helps detect Alzheimer’s early on. The Nestle Institute of Health Sciences (NIHS) has developed a proprietary platform and is now moving to deploy it for the development of an assay to detect Alzheimer’s disease early on. According to recent estimates, over 44 mn people worldwide reportedly suffer from Alzheimer’s disease.

To this end, the NIHS inked an agreement with AC Immune SA, a France-based biopharmaceutical company, to develop a test that would identify tangles of Tau proteins. Based on previous research, scientists at Nestle say that Tau proteins are among the two most prominent symptoms of neurodegeneration.

Thus, by developing a diagnostic device that can spot this important causative factor, Nestle expects to break into a space that has not been commercially exploited thus far in the Alzheimer’s diagnosis field. Beta-amyloid plaques are the other important hallmark of neurodegeneration. Nestle’s strategy is to use the Tau proteins as a biomarker to aid the detection and diagnosis of Alzheimer’s.

Ed Baetge, who heads the NIHS, said that its latest deal with AC Immune will open up several new growth avenues through which it hopes to grab a share in the expanding revenue pie of the medical devices industry. He described the next-generation Nestle platform as being “ultrasensitive.” The test will be minimally invasive and will use blood samples from patients to detect the disease. Tau said that proprietary diagnostic technology was acquired along with its acquisition of Prometheus Laboratories in 2011. The NIHS says that it has been using the technology in its various brain research programs since the last two years.